Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Women's HealthIssue 612

50GM Glucose Challenge Test an Acceptable Screen for Gestational Diabetes

The 50-g glucose challenge test is an "acceptable" screening test for GDM but it can't replace the OGTT....

Advertisement

GDM affects between 2% and 9% of pregnant women in Western countries and is often asymptomatic. Research has shown that treating GDM with diet or insulin improves both perinatal and maternal outcomes, making detection important. Yet the best way to identify women with GDM is unclear.

In their report, Dr. Marsha van Leeuwen from Academic Medical Center, Amsterdam and colleagues say that while the 50-g glucose challenge test is not recommended in the majority of national guidelines, "it could be a useful test in the diagnostic work up of GDM."

In a systematic review and meta-analysis, they evaluated it as a first-step screening test for GDM and as a replacement for the OGTT, the current diagnostic test.

Altogether they looked at 26 relevant studies (in 13,564 women) that compared the 50-g glucose challenge test to the OGTT before 32 weeks gestation. The reference standard was the 75-g OGTT in six studies and the 100-g OGTT in the other 20 papers.

In studies of women with risk factors for GDM, such as a prior affected pregnancy, the 50-g glucose challenge test had a pooled sensitivity of 0.74 and a pooled specificity of 0.77 (for a threshold value of 7.8 mmol/L). The test had "modest" accuracy for GDM, with positive and negative likelihood ratios of 3.2 and 0.34, respectively, the researchers say.

Results were similar in studies that consecutively recruited participants, with sensitivity, specificity and positive and negative predictive likelihood ratios of 0.74, 0.85, 4.9 and 0.31, respectively.

The researchers found that increasing the threshold for disease (OGTT result) increased the sensitivity of the challenge test and decreased the specificity.

Dr. van Leeuwen and colleagues say that while higher detection rates "would be preferable," the 74% detection rate of the 50-g glucose challenge test "might be acceptable if used a screening test."

They emphasize, however, that to use the 50-g glucose challenge test as a definite diagnostic test for GDM, in place of the OGTT, "higher accuracy measures are warranted."

On the other hand, they say clinicians could consider a one-step method, using the OGTT for screening for example in selected women, such as those with risk factors for GDM. This could be less burdensome for patients, and more cost-effective than a two-step method in which a glucose loading test might be performed twice.

Online January 20 in the British Journal of Obstetrics and Gynecology (BJOG)

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 08 February, 2012 and appeared in  Women's HealthIssue 612

Past five issues: Issue 796 | Diabetes Clinical Mastery Series Issue 255 | Issue 795 | SGLT-2 Inhibitors Special Edition August 2015 | Diabetes Clinical Mastery Series Issue 254 |

2015 Most Popular Articles:

Coffee Consumption Proves Potential in Reducing Type 2 Diabetes Risk
Posted August 07, 2015
Impaired Glucose Uptake in the Brain May Increase Alzheimer's Disease Risk
Posted August 07, 2015
First Non-Surgical Weight Loss Procedure for Mild-to-Moderate Obesity
Posted August 07, 2015
GLP-1 Agonist Semaglutide Completes Phase III Trial with Positive Results
Posted August 07, 2015
Impact of Switching Insulin Glargine to Insulin Detemir in T2 Patients
Posted August 14, 2015
Ketoacidosis Not as Great as Thought in Diabetes Patients Taking Invokana
Posted August 13, 2015
Two New Possible Methods for Diagnosing and Monitoring Diabetes
Posted August 07, 2015
SIgnificant Weight Gain Associated with Laparoscopic Sleeve Gastrectomy
Posted August 14, 2015
Diabetes Combination Drug LixiLan Meets Main Target in Late Stage Trial
Posted August 07, 2015
A Telltale Sign of Type 2 Diabetes
Posted August 07, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
What percentage of your patients have reached goal for A1c, BP and cholesterol?

CME/CE of the Week
Presented by CardioCareLive
Category: Cardiology